Merck & Co., Inc.MRKNYSE
Loading

Analyst Sentiment

Analysts lean bullish — 64% recommend buying.

Consensus Rating
Buy
25 analysts·High coverage
64%
Rating Distribution
Strong Buy
00%
Buy
1664%
Hold
832%
Sell
14%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case
$90.00
-26%
Consensus
$123.92
+2%
Bull Case
$150.00
+24%
Price Range25 analysts
Low
Consensus
High
$90.00
$150.00
Current Target
Current Price
$121.41
Upside to Target
$2.51

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$5.11(14 analysts)
P/E17x
Current: 16.9x
Actual
Estimate
Range (Low–High)
Stock Alarm Pro
Forward Growth Estimates (YoY)
FY2027
Rev+5.14%
EPS+89.58%
FY2028
Rev+6.53%
EPS+10.87%
FY2029
Rev-0.37%
EPS-3.99%

Earnings Surprises

Beat rate:92%(11/12 quarters)
Avg surprise:+15.6%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 24, 2026RBC Capital
RBC Capital Starts Merck (MRK) at Outperform
Target:$142.00
+14.6%from $123.93
Feb 13, 2026Deutsche Bank
Merck upgraded to Buy from Hold at Deutsche Bank
Target:$150.00
+23.4%from $121.53
Feb 4, 2026Goldman Sachs
Merck price target raised to $133 from $120 at Goldman Sachs
Target:$133.00
+14.8%from $115.86
Feb 4, 2026BMO Capital
Merck price target raised to $135 from $130 at BMO Capital
Target:$135.00
+16.5%from $115.86
Feb 4, 2026Bernstein
Merck price target raised to $100 from $95 at Bernstein
Target:$100.00
-13.7%from $115.86
Feb 3, 2026Scotiabank
Merck price target raised to $136 from $120 at Scotiabank
Target:$136.00
+16.9%from $116.37
Jan 27, 2026Cantor Fitzgerald
Merck price target raised to $116 from $83 at Cantor Fitzgerald
Target:$116.00
+8.0%from $107.40
Jan 8, 2026Wolfe Research
Merck upgraded to Outperform from Peer Perform at Wolfe Research
Target:$135.00
+24.3%from $108.59
Jan 7, 2026UBS
Merck price target raised to $130 from $105 at UBS
Target:$130.00
+17.2%from $110.96
Dec 18, 2025BMO Capital
Merck upgraded to Outperform from Market Perform at BMO Capital
Target:$130.00
+31.0%from $99.21
Dec 12, 2025Morgan Stanley
Merck price target raised to $102 from $100 at Morgan Stanley
Target:$102.00
+1.9%from $100.06
Dec 10, 2025HSBC
Merck price target raised to $120 from $100 at HSBC
Target:$120.00
+23.9%from $96.89
Dec 5, 2025Guggenheim
Merck price target raised to $122 from $104 at Guggenheim
Target:$122.00
+20.9%from $100.89
Dec 4, 2025Scotiabank
Merck price target raised to $120 from $105 at Scotiabank
Target:$120.00
+17.8%from $101.88
Dec 2, 2025Goldman Sachs
Merck price target raised to $120 from $92 at Goldman Sachs
Target:$120.00
+17.8%from $101.83
Nov 3, 2025Morgan Stanley
Merck price target raised to $100 from $98 at Morgan Stanley
Target:$100.00
+18.1%from $84.65
Sep 17, 2025Berenberg Bank
Merck downgraded to Hold from Buy at Berenberg
Target:$90.00
+10.9%from $81.14
Jul 10, 2025Morgan Stanley
Merck price target lowered to $98 from $99 at Morgan Stanley
Target:$98.00
+16.1%from $84.39
Apr 25, 2025BMO Capital
Merck price target lowered to $82 from $89 at BMO Capital
Target:$82.00
-0.9%from $82.74
Feb 5, 2025Morgan Stanley
Merck price target lowered to $106 from $113 at Morgan Stanley
Target:$106.00
+16.8%from $90.74
Dec 2, 2024Bernstein
Merck (MRK) PT Lowered to $110 at Bernstein SocGen Group as 'Gardasil overhang continues'
Target:$110.00
+9.2%from $100.69
Nov 15, 2024Jefferies
Merck (MRK) PT Raised to $148 at Jefferies
Target:$148.00
+50.5%from $98.36
Nov 1, 2024BMO Capital
Merck (MRK) PT Lowered to $136 at BMO Capital
Target:$136.00
+33.5%from $101.88
Oct 9, 2024UBS
Merck price target lowered to $136 from $142 at UBS
Target:$136.00
+24.9%from $108.88
Oct 7, 2024Barclays
Merck price target lowered to $140 from $142 at Barclays
Target:$140.00
+27.5%from $109.77